On the origin of the giant isotopic effect of hydrogen on the magnetic properties of YFe2A4.2 (A5H, D): A high pressure study

International audienceIn order to identify the origin of the giant isotope effect observed on the magnetic properties of YFe2A4.2 compounds (A¼H, D) and probe the role of the cell volume difference, we have compared the effect of hydrostatic pressure up to 1.0 GPa on the ferro-antiferromagnetic transition temperatures TF-AF and spontaneous magnetization of YFe2D4.2 and YFe2H4.2. Using compressibility value of 0.013 GPa 1 and the remarkably different negative pressure slopes of TF-AF, the existence of critical volume where the ferromagnetism is suppressed at 0K, VC¼501.760.3 ˚A3, was demonstrated. This consequently established the crucial role of volume on the huge isotope effect observed on the magnetic properties

Nondiffracting beams for vortex tomography

We propose a reconstruction of vortex beams based on the implementation of quadratic transformations in the orbital angular momentum. The information is encoded in a superposition of Bessel-like nondiffracting beams. The measurement of the angular probability distribution at different positions allows for the reconstruction of the Wigner function.Comment: 3 pages. 2 eps figures. To appear in Optics Letter

Co and In Doped Ni-Mn-Ga Magnetic Shape Memory Alloys: A Thorough Structural, Magnetic and Magnetocaloric Study

In Ni-Mn-Ga ferromagnetic shape memory alloys, Co-doping plays a major role in determining a peculiar phase diagram where, besides a change in the critical temperatures, a change of number, order and nature of phase transitions (e.g., from ferromagnetic to paramagnetic or from paramagnetic to ferromagnetic, on heating) can be obtained, together with a change in the giant magnetocaloric effect from direct to inverse. Here we present a thorough study of the intrinsic magnetic and structural properties, including their dependence on hydrostatic pressure, that are at the basis of the multifunctional behavior of Co and In-doped alloys. We study in depth their magnetocaloric properties, taking advantage of complementary calorimetric and magnetic techniques, and show that if a proper measurement protocol is adopted they all merge to the same values, even in case of first order transitions. A simplified model for the estimation of the adiabatic temperature change that relies only on indirect measurements is proposed, allowing for the quick and reliable evaluation of the magnetocaloric potentiality of new materials starting from readily available magnetic measurements

Direct and indirect measurement of magnetocaloric effect in NiCoMnGa alloys

The Co-substitution for Ni in the Mn-rich NiMnGa Heusler alloys changes substantially their structural and magnetic ordering. The results will be discussed within the basic thermodynamic relations

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.Peer reviewe

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation